Non-muscle Invasive Bladder Cancer Clinical Trial
Official title:
A Single Dose, Dose-escalating, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Intravesical Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of intravesical cis-urocanic acid in patients with primary or recurrent non-muscle invasive bladder cancer.
This is a single dose, dose-escalating, Phase I study to evaluate safety, tolerability and
pharmacokinetics of intravesical cis-urocanic acid (cis-UCA) in patients with primary or
recurrent non-muscle invasive bladder cancer.
The primary objectives is to evaluate safety and tolerability of cis-UCA after a single
intravesical instillation with escalating doses and to determine the maximum tolerated dose
(MTD) and dose-limiting toxicity (DLT) of cis-UCA after a single intravesical instillation
with escalating doses.
The secondary objectives are to evaluate pharmacokinetics of cis-UCA after a single
intravesical instillation with escalating doses, to obtain preliminary information on
possible anti-tumor effects of cis-UCA by cystoscopy and histological evaluation after a
single intravesical instillation with escalating doses, and to evaluate the effects of
cis-UCA on different surrogate biochemical markers on tumor growth and differentiation after
a single intravesical instillation with escalating doses.
The key eligibility criteria are the following: Patients with primary or recurrent
non-muscle invasive bladder cancer; eligible for intravesical treatment; age 18-80 years;
WHO performance status 0-2; acceptable liver, renal and hematological function within 30
days prior to inclusion.
At minimum 3 patients and at maximum 24 patients is planned to be included in the study. The
fixed dose-escalation levels will be used.
Up to three dose cohorts are planned to be included:
- Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
- Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
- Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04736394 -
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
|
Phase 3 | |
| Recruiting |
NCT05951179 -
Dose Expansion, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04943094 -
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
|
||
| Not yet recruiting |
NCT06227065 -
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
|
Phase 2 | |
| Completed |
NCT02969109 -
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
|
||
| Recruiting |
NCT03914794 -
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
|
Phase 2 | |
| Recruiting |
NCT05126472 -
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
|
Phase 1 | |
| Recruiting |
NCT04644835 -
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer
|
N/A | |
| Recruiting |
NCT06126796 -
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
|
||
| Active, not recruiting |
NCT04100733 -
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
|
N/A | |
| Recruiting |
NCT05085990 -
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 1 | |
| Recruiting |
NCT03560479 -
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04498702 -
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
|
Phase 2 | |
| Recruiting |
NCT05337397 -
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
|
||
| Active, not recruiting |
NCT04490993 -
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
|
Phase 3 | |
| Recruiting |
NCT04859751 -
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
| Recruiting |
NCT05672615 -
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
|
||
| Not yet recruiting |
NCT06245603 -
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
|
N/A |